Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Boosted by New York Life Investment Management LLC

New York Life Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,087 shares of the biopharmaceutical company’s stock after purchasing an additional 1,144 shares during the quarter. New York Life Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $11,645,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of REGN. WPG Advisers LLC boosted its stake in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Caitlin John LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $34,000. FNY Investment Advisers LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $38,000. Finally, Torren Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $38,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN opened at $698.25 on Friday. The stock has a fifty day moving average of $744.69 and a 200-day moving average of $744.97. The firm has a market capitalization of $73.82 billion, a P/E ratio of 17.01, a PEG ratio of 1.58 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.22 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.1 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 6.97% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on REGN shares. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Royal Bank Of Canada reduced their price objective on Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating for the company in a research note on Thursday, April 30th. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Finally, Evercore raised their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $826.59.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.